SCHEMBL2353506

SCHEMBL2353506

COc1cc(CCOP(=O)(OCc2ccccc2)OCc2ccccc2)ccc1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX5 P09917 2/20 0.52
▸ PTPN1 P18031 2/20 0.51
▸ TAAR1 Q96RJ0 2/20 0.50
▸ TSHR P16473 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ GAA P10253 3/20 0.49
▸ TRPV1 Q8NER1 2/20 0.49
▸ ATM Q13315 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ GLA P06280 1/20 0.49
▸ POLB P06746 1/20 0.48
▸ OR51E2 Q9H255 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ NOS2 P35228 1/20 0.47
▸ TTR P02766 1/20 0.46
▸ ADRB2 P07550 1/20 0.46
▸ DRD2 P14416 1/20 0.46
▸ DRD1 P21728 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2350252 0.89 TAAR1 (0.61) ALOX5PTPN1TAAR1TSHRMAPK1
SCHEMBL2352673 0.83 MTNR1A (0.48) TSHRPOLBALDH1A1
SCHEMBL2351355 0.83 GSK3B (0.45) MAPK1LMNAADRB2
SCHEMBL2350254 0.80 TAAR1 (0.59) ALOX5PTPN1TAAR1TSHRMAPK1
SCHEMBL2351871 0.80 ESR1 (0.54) TSHRLMNA
SCHEMBL23754156 0.78 PTPN1 (0.70) ALOX5PTPN1TAAR1TSHRMAPK1
SCHEMBL16355871 0.78 PTPN1 (0.70) ALOX5PTPN1TAAR1TSHRMAPK1
SCHEMBL11120021 0.78 TSHR (0.55) TSHRTDP1
SCHEMBL12204003 0.76 TAAR1 (0.71) ALOX5PTPN1TAAR1TSHRMAPK1
SCHEMBL31512881 0.75 TSHR (0.57) ALOX5PTPN1TAAR1TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2348859-B1 PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS MERCK SHARP & DOHME (US) 2013-12-04 — — EP disclosed
US-8354454-B2 Prodrugs of oxazolidinone CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2013-01-15 — — US disclosed
US-20110218177-A1 PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS MERCK SHARP & DOHME LLC 2011-09-08 — — US disclosed
EP-2348859-A1 PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS Merck Sharp & Dohme Corp. (US) 2011-08-03 — — EP disclosed
WO-2010039474-A1 PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS MERCK SHARP & DOHME CORP. (US) 2010-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218177-A1 PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS CETP, SLCO2B1, OXA1L ALOX5 1624/4885PTPN1 3168/4885TAAR1 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback